The Securities and Exchange Commission has charged a trader with using fraudulent posts on Twitter to manipulate the stock price of Sarepta Therapeutics. James Alan Craig, the man at the center of the case, is alleged to have created a Twitter account that looked like it belonged to securities research firm Citron Research and used it to post lies about Sarepta.
GlaxoSmithKline has provided a glimpse at just how much information about the real-world use of drugs is online. In a trawl of Facebook and Twitter, the Big Pharma found 21 million mentions of its products--and the data have already led to the recall of a GSK product.
Tweet on, drugmakers. Not only is Twitter use by pharma companies on the rise, but so is interest in what they've got to say. A recent survey by the Eye on FDA blog found more daily interactions on Twitter by pharma, along with a marked increase in followers versus last year.
Back when Martin Shkreli was CEO of Retrophin, he managed to grab a few headlines by buying an old rare-disease drug, Thiola, and raising the price 2000%. Now that he's on to his next company, Turing Pharmaceuticals, he's done himself one better, by buying another old drug and boosting the price 5000%.
Pharma execs are still sitting on the social media sidelines, according to one new assessment. BrandFog social media consultancy has come up with its first top 20 list of healthcare and pharma Twitter influencers and not one pharma company staffer is on it.
A congressman is taking aim at perceived flaws in FDA's long-awaited, much-discussed guidance on the use of Twitter.
IBM has made another foray into healthcare research. The latest collaboration sees the tech veteran team up with Cleveland Clinic to use Watson in genomics cancer research.
The window for commenting on the FDA's draft guidance on pharma's use of Twitter and other social media slammed shut last week, leaving the agency with a stack of feedback to consider. Many of the respondents are unhappy with the draft, which was called unconstitutional and overbroad.
Having had a week to mull over the FDA's latest batch of social media guidance, some observers have concluded the agency is making a blunt statement to brand managers: Don't use Twitter.
Any brand managers eager to jump into Twitter as soon as the FDA gave the go-ahead? No such luck. Last week's social media guidance on risk disclosures may have cleared up some of the regulatory fog, but in this case, clarity isn't a positive.